Towards better non-selectivity: The role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - Lurasidone;W kierunku lepiej zaplanowanej nieselektywnöci: Rola receptorów 5-HT7 w działaniu leku przeciwpsychotycznego II generacji - Lurazydonu

Psychiatria Polska

Volumn 49, Issue 2, 2015, Pages 243-253

  Bieńkowski, Przemysław ^a,d   Dudek, Dominika ^b   Samochowiec, Jerzy ^c  

^a Zaklad Farmakologii   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

5 ht7 receptors; Bipolar depression; Lurasidone; Schizophrenia; Serotonin receptors

Indexed keywords

LURASIDONE; SEROTONIN 7 RECEPTOR; ANTIPSYCHOTIC AGENTS; ISOINDOLES; RECEPTORS, SEROTONIN; THIAZOLES;

ARTICLE; DRUG EFFICACY; HUMAN; PATIENT SATISFACTION; TREATMENT RESPONSE; ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITION; DRUG EFFECTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; COGNITION; HUMANS; ISOINDOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; THIAZOLES;

EID: 84928787414     PISSN: 00332674     EISSN: 23915854     Source Type: Journal    
DOI: 10.12740/PP/38250     Document Type: Article

References (41)

1. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin. Schizophr. Rel. Psychoses 2011; 4: 251-257.
2. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 2011; 11: 59-67.
3. Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther. Clin. Risk Manag. 2011; 7: 239-250.
4. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA. Newer antipsychotics and upcoming molecules for schizophrenia. Eur. J. Clin. Pharmacol. 2013; 69: 1497-1509.
5. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS. i wsp. Asenapine, blonanserine, iloperidone, lurasidone and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin. Neuropharmacol. 2013; 36: 223-238.
6. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P. Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. Mol. Neurobiol. 2011; 43: 228-253.
7. Gellynck E, Heyninck K, Andressen KW, Haegeman G, Levy FO, Vanhoenacker P. i wsp. The serotonin 5-HT7 receptors: two decades of research. Exp. Brain Res. 2013; 230: 555-568.
8. Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 2004; 25: 481-486.
9. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 2009; 206: 345-354.
10. Wesołowska A, Tatarczyńska E, Nikiforuk A, Chojnacka-Wójcik E. Enhancement of the antiimmobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur. J. Pharmacol. 2007; 555: 43-47.
11. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 2009; 205: 119-128.
12. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorders. Neuropsychiatry Dis. Treat. 2013; 9: 1521-1529.
13. Sumiyoshi T. Antipsychotic treatments; focus on lurasidone. Front. Pharmacol. 2013; 4: 102.
14. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R. i wsp. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010; 334: 171-181.
15. Kołaczkowski M, Mierzejewski P, Bieńkowski P, Wesołowska A, Newman-Tancredi A. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch. Pharmacol. 2014; 387: 545-557.
16. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB. Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology 2013; 70: 211-217.
17. Wesołowska A, Nikiforuk A, Stachowicz K. Potential anxiolytic and antidepressant effects of the selective 5-HT7 receptor antagonist SB 269970 after intrahippocampal administration to rats. Eur. J. Pharmacol. 2006; 553: 185-190.
18. Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R. i wsp. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J. Pharmacol. Exp. Ther. 2007; 321: 690-698.
19. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J. Affect. Disord. 1998; 48: 47-56.
20. Hardoy MC, Carta MG. Strategy to accelerate or augment the antidepressant response and for an early onset of SSRI activity. Adjunctive amisulpride to fluvoxamine in major depressive disorder. Clin. Pract. Epidemiol. Ment. Health 2010; 6: 1-3.
21. Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG. Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders. CNS Neurosci. Ther. 2014; 20: 582-590.
22. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv. Ther. 2012; 29: 815-825.
23. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr. Dis. Treat. 2014; 10: 1297-1307.
24. Chang T, Fava M. The future of psychopharmacology of depression. J. Clin. Psychiatry 2010; 71: 971-975.
25. Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology 2011; 213: 289-305.
26. Loebel A, Cucchiaro J, Xu J, Sarma K, Pikalov A, Kane JM. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr. Res. 2013; 147: 95-102.
27. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013; 45: 54-63.
28. Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur. Neuropsychopharmacol. 2013; 23: 1373-1382.
29. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur. J. Pharmacol. 2007; 572: 160-170.
30. Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T. i wsp. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav. Brain Res. 2011; 220: 83-90.
31. Horiguchi M, Huang M, Meltzer HY. The role of 5-hydroxytryptamine7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther. 2011; 338: 605-614.
32. Murai T, Nakako T, Ikejiri M, Ishiyama T, Taiji M, Ikeda K. Effects of lurasidone on executive function in common marmosets. Behav. Brain Res. 2013; 246: 125-131.
33. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J. i wsp. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 2011; 168: 957-967.
34. Yasui-Furukori N. Update of the development of lurasidone as a treatment for patients with acute schizophrenia. Drug Design Devel. Ther. 2012; 6: 107-115.
35. Citrome L, Weiden PJ, Correl CU, Cucchiaro J, Hsu J, Loebel A. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr. 2014; 19: 330-339.
36. Mierzejewski P, Nowak N, Głębicka A, Karas K, Kołaczkowski M, Bieńkowski P. Lurasidone in contrast to other antipsychotics does not produce deficits in social exploration and social recognition in the rat. Poster presented at the 29th CINP Congress of Neuropsychopharmacology, Vancouver, Canada, 2014.
37. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J. Affect. Disord. 2013; 155: 20-27.
38. Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K. i wsp. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014; 171: 160-168.
39. Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J. i wsp. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014; 171: 169-177.
40. Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2014; 23: 1-8.
41. Hopkins CR. ACS Chemical Neuroscience molecule spotlight on Latuda (Lurasidone; SM- 13,496). ACS Chem. Neurosci. 2011; 2: 58-59.